Til Stürmer, MD, MPH; Julie E. Buring, ScD; Robert J. Glynn, PhD, ScD
Potential Financial Conflicts of Interest: Dr. Stürmer receives investigator-initiated research funding and support as principal investigator from the National Institute of Aging, National Institutes of Health. Dr. Buring has received investigator-initiated research funding and support as principal investigator from the National Institutes of Health (National Heart, Lung, and Blood Institute; National Cancer Institute; and National Institute of Aging) and Dow Corning Corporation; research support for pills and/or packaging from Bayer HeathCare and the Natural Source Vitamin E Association; and honoraria from Bayer for speaking engagements. She also serves on an external scientific advisory committee for a study by Procter & Gamble. Dr. Glynn receives investigator-initiated research funding and support as principal investigator from the National Institute of Aging and the National Heart, Lung, and Blood Institute, National Institutes of Health. Drs. Stürmer and Glynn do not accept personal compensation from any pharmaceutical company, although they receive salary support from unrestricted research grants from pharmaceutical companies to the Brigham and Women's Hospital.
Til Stürmer, Julie E. Buring, Robert J. Glynn. Aspirin and Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: Weighing the Evidence. Ann Intern Med. 2007;147:674. doi: 10.7326/0003-4819-147-9-200711060-00022
Download citation file:
Published: Ann Intern Med. 2007;147(9):674.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use